Cardiology
September 11, 2025
Cardiac Wire’s ASE 2025 Takeaways September 11, 2025
The American Society of Echocardiography left an echo this year in Music City as it celebrated its 50th year. Among the studies and products unveiled at ASE 2025, here are Cardiac Wire’s top five takeaways from the meeting. Premium Echo Has Found its Stride – Although most typically think of ultrasound as a lower cost […]
Cardiology Business
September 8, 2025
Edwards Acquires Vectorious, Bolsters HF Portfolio September 8, 2025
Edwards Lifesciences took another step towards becoming a major player in remote heart failure monitoring, after fully acquiring Israeli startup Vectorious Medical Technologies for $497M in cash. Vectorious’ monitoring device is known as the V-LAP system and it uses a minimally invasive approach to achieve continuous HF monitoring through a tiny, battery-free sensor implanted in […]
Cardiology Pharmaceuticals
September 4, 2025
The Differences in HCM, Results from ODYSSEY and MAPLE September 4, 2025
In a big step towards better hypertrophic cardiomyopathy treatments, two separate studies presented at ESC suggest cardiac myosin inhibitors’ efficacy depends critically on whether patients have the obstructive or nonobstructive form of the disease. Two different trials presented insightful outcomes at ESC 2025, with MAPLE-HCM testing aficamten versus metoprolol in obstructive HCM patients, and ODYSSEY-HCM […]
Cardiology
August 28, 2025
Cardiologists, Practice What You Preach! August 28, 2025
Cardiologists might be struggling with the same lifestyle challenges they counsel patients about, as a national survey of ACC members revealed significant gaps between what physicians’ recommend and how they act. The ACC CardioSurve study surveyed 166 U.S. cardiologists about their training in lifestyle medicine and clinical recommendations across all six lifestyle pillars, revealing some […]
Obesity Care
August 25, 2025
GLP-1s Work, But Not for Free August 25, 2025
Real-world semaglutide (Wegovy) patients might be experiencing a healthcare cost paradox, after a recent analysis in JAMA showed that GLP-1s successfully reduce weight and improve cardiovascular risk factors, but lead to increased patient healthcare expenditures in the short term. The real-world analysis examined 23.5k adults prescribed semaglutide between January 2018 and January 2025 across two […]
Electrophysiology
August 21, 2025
Conduction-System Pacing Succeeds at Treating AV Block August 21, 2025
Conduction-system pacing could be poised to reshape standard care for atrioventricular (AV) block patients after the randomized CSPACE trial demonstrated its significant benefits over traditional right ventricular septal pacing. Taking a closer look at CSP’s potential, the CSPACE trial enrolled 202 patients with AV block at two Australian hospitals, randomizing them to conduction-system pacing or […]
Cardiology Pharmaceuticals
August 18, 2025
Rivaroxaban Monotherapy Could Be Better for CAD + AFib August 18, 2025
New analysis from the AFIRE trial suggests rivaroxaban monotherapy might be emerging as a preferred antithrombotic strategy for patients with AFib and stable coronary artery disease, especially in older age groups. The Post Hoc AFIRE Analysis examined 2,215 Japanese patients with AFib and stable CAD, stratifying them into four age groups (<70, 70-74, 75-79, and […]
Surgeries & Interventions
August 14, 2025
TEER Could Save Lives in AFMR Patients August 14, 2025
Shedding light on a new treatment for an understudied condition, data published in EHJ suggests that transcatheter edge-to-edge repair (TEER) delivers significant survival advantages in patients with atrial functional mitral regurgitation (FMR). The new OCEAN-Mitral/REVEAL-AFMR Analysis compared 441 TEER-treated patients against 640 medically managed controls with moderate or severe atrial FMR, stating a solid case […]
Cardiology Business
August 11, 2025
The State of the TAVR Market in 2025 August 11, 2025
2025 has been a year of many cardiology trends, with one stand out technology capturing much of the spotlight – transcatheter aortic valves. To keep our valves in a row, Cardiac Wire has compiled a breakdown of the top TAVR makers, movers, shakers, and potential future players. Starting off with the biggest player, Edwards Lifesciences […]
Cardiology Pharmaceuticals
August 7, 2025
SURPASS-CVOT Shows Mounjaro Surpasses Trulicity in CV Outcomes August 7, 2025
The largest and longest tirzepatide study to date just confirmed that Eli Lilly’s Mounjaro has surpassed its older GLP-1, Trulicity, in practically every way, with significant gains when it comes to cardiovascular benefits. The SURPASS-CVOT study represents the most comprehensive incretin analysis to date, comparing MACE rates in 13k T2D patients with ASCVD on either […]
Cardiovascular Disease
August 4, 2025
The Impact of Physical Activity Before and After CV Events August 4, 2025
A long-term analysis of the CARDIA study revealed that moderate-to-vigorous physical activity steadily declines from young adulthood through midlife, but patients destined to develop cardiovascular disease experience rapid activity decreases more than a decade before their first event. Collecting data over 37 years, researchers tracked ~3k participants from young adulthood to middle age and paired […]
Cardiology Pharmaceuticals
July 31, 2025
AstraZeneca’s Anselamimab Comes Up Short in Phase 3 Trial July 31, 2025
In a setback to one of its rarer disease pipelines, AstraZeneca’s amyloidosis antibody, anselamimab, failed to significantly reduce all-cause mortality and CV hospitalizations in the CARES Phase 3 trial’s overall patient population. The CARES clinical program was the largest prospective cardiac AL amyloidosis investigation to date, enrolling 406 patients to test whether anselamimab could reduce […]